Efficacy and safety of granulocyte-macrophage colony-stimulating factor (GM-CSF) antibodies in COVID-19 patients: a meta-analysis.

ABSTRACT:

Objective

This study aims to determine the efficacy and safety of granulocyte-macrophage colony-stimulating factor (GM-CSF) antibodies in COVID-19 patients.

Methods

We searched Cochrane Library, PubMed, Embase, and ClinicalTrials.gov databases until July 27, 2022. Both randomized control trials (RCTs) and cohort studies were included and analyzed separately. The outcomes included mortality, incidence of invasive mechanical ventilation (IMV), ventilation improvement rate (need oxygen therapy to without oxygen therapy), secondary infection, and adverse events (AEs). The odds ratio (OR) with a 95% confidence interval (CI) was calculated by a random-effects meta-analysis model.

Results

Five RCTs and 2 cohort studies with 1726 COVID-19 patients were recruited (n = 866 in t

SUBMITTER: Xi AR 

PROVIDER: S-EPMC9707187 | biostudies-literature | 2023 Feb

REPOSITORIES: biostudies-literature